Objectives: Prostate biopsy involvement and Gleason score guide treatment decisions in prostate cancer. We evaluated concordance in Gleason score and laterality between biopsy and radical retropubic prostatectomy (RRP) specimens and factors that influenced this relationship.
INTRODUCTION
Prostate cancer is common in men with an estimated 218,890 new diagnoses and 27,050 deaths in 2007 (1) . The pathologic diagnosis of prostate cancer is based on transrectal ultrasound guided prostate biopsy which provides information on Gleason grade and unilateral versus bilateral cancer involvement. Gleason grade and prostate biopsy involvement subsequently guide treatment decisions, and influence surgical decisions with respect to nerve-sparing and Clinical Urology pelvic lymph node dissection at the time of radical retropubic prostatectomy (RRP). Because of a trend in the PSA era toward patients presenting with low PSA levels and nonpalpable disease, pretreatment Gleason score may be the most important prognostic factor for treatment response and patient outcome (2) .
It is important for clinicians to have information regarding the accuracy of prostate biopsy specimens. Prior studies have suggested that taking more prostate cores may improve the concordance between biopsy and prostatectomy (2-5), while others have not found such a relationship (6) . Our main study objective was to evaluate concordance of Gleason score and laterality between prostate biopsy and RRP specimens in a cohort of our patients. A secondary objective was to evaluate whether an increased number of cores improved concordance.
MATERIALS AND METHODS
We retrospectively reviewed 538 prostate cancer diagnoses at the Veterans Affairs Medical Center Iowa City from 2000-2005 to identify men who underwent RRP. Patients were excluded if prostatectomy was not performed or if pathology reports from both prostate biopsy and RRP specimens were not available. Prostate biopsies were obtained using transrectal ultrasound guidance and the number of cores taken was at the discretion of the clinician. Clinical and pathologic data was reviewed for information including pathology reports from prostate biopsy and RRP. PSA value prior to biopsy was used for analysis. Number of days from initial biopsy to RRP was calculated for each patient. We defined concordance as an exact match in grade (or laterality) from biopsy to corresponding RRP specimen. Discordance was defined as a difference in grade (or laterality) from biopsy to RRP (i.e. upgrading from Gleason 3+4 to 4+3 was considered discordant).
Analysis was performed using the chi-square or Fisher's exact test for categorical variables and the Wilcoxon rank sum test for ordinal or continuous variables. P < 0.05 was considered significant. Statistical analysis was performed using SigmaStat 3.5. Institutional Review Board approval for the study was obtained.
RESULTS
Of the 538 men diagnosed with prostate cancer during the index period (2000) (2001) (2002) (2003) (2004) (2005) , 152 met inclusion criteria and underwent RRP ( Table-1) . Prostate biopsy was Gleason < 7 in 56%, 7 in 36%, and > 7 in 8%. Biopsy involvement was unilateral in 90 (59%) and bilateral in 62 (41%). During the time period of this study, there was a general move from limited (6 core) to extended (12 core) biopsy schemes ( Figure-1) .
Average age at RRP was 61.3 years (median 61.2, range 44.1 to 74.5). Compared to biopsy, RRP Gleason score was concordant in 76 (50%), upgraded in 51 (34%), and downgraded in 25 (16%). Of those 51 patients who had Gleason score upgraded on RRP, Gleason grade was increased by < 1 grade in 7, 1 grade in 39, and > 1 grade in 5 patients. In the 25 patients who had Gleason score downgraded on RRP, Gleason grade was decreased by < 1 grade in 10, 1 grade in 13, and > 1 grade in 2 patients.
Concordance was not affected by age, PSA, prostate volume, or length of time from biopsy to RRP (Table-2 ). However, differences were noted for Gleason sum 7 biopsies, as Gleason 3+4 concordance was 67% (30 of 45) with upgrading in 22% (10 of 45) and downgrading in 11% (5 of 45) versus Gleason 4+3, which was concordant in none (0 of 10) with upgrading in 20% (2 of 10) and downgrading in 80% (8 of 10) (p < 0.001).
Gleason concordance was higher in those with 8 or more cores compared to < 8 cores taken (54% vs. 34%, p = 0.046). Table-3 shows the concordance rate stratified by number of cores. The highest accuracy rate was in the group with 8-9 cores, with a statistically significant improvement in accuracy from 34% to 64% seen when going from 5-7 to 8-9 cores (p = 0.03). Despite the increase in cores taken per patient in each subsequent year during our study ( Figure-1) , an incremental increase in accuracy over time was not observed ( Table-4 ). When biopsy involvement was unilateral, 72 of 90 (80%) actually had bilateral involvement on RRP (Figure-2 ). In patients with bilateral biopsy involvement, 60 of 62 (97%) had bilateral involvement on prostatectomy. Both Gleason score and laterality were concordant in only 26%.
COMMENTS
Findings on prostate biopsy can differ from findings on RRP, and accurate assessment of prostate cancer on biopsy is important because it guides treatment decisions. Patients with low-grade prostate cancer are more likely to be offered expectant management without active treatment (7). Patients with higher grade involvement on prostate biopsy are more likely to have pelvic lymph node dissection performed and less likely to be offered nerve-sparing prostatectomy. We evaluated patients who underwent prostatectomy, and found that prostate biopsy underestimated Gleason score in 34% of men and bilateral involvement in 80% of those with unilateral disease on biopsy. These differences may be due to sampling error, pathologist's interpretation, or disease progression (8) . In our study, there was a general trend toward increased concordance when more prostate core biopsies were performed as the concordance rate was lowest in the 5-6 core group. Prior studies have suggested that taking more prostate cores may improve the concordance between biopsy and prostatectomy (2-5), while others have argued that more cores does not improve prognostic information (6). Coogan et al. reported 10 cores provided an accuracy of 58% versus 40-41% in those with 8 and 6 cores (4). San Francisco et al. reported an extended biopsy regimen with 10 or more cores improved concordance from 63% to 76%, and also proposed that processing each prostate core separately also improved accuracy (3) . Similarly, Mian et al. noted improvement in accuracy from 48% to 68% when more than 6 cores were taken (2) . One study of 100 consecutive prostatectomy specimens evaluated by core biopsy of the surgical specimens on the bench top reported that prostate cancer detection improved from 75% with sextant biopsies to 88% with an extended 14 core biopsy (9) . Despite the suggestion that taking more cores directly leads to increased accuracy, the relationship is likely multi-factorial. Toward the later years of our study, more prostate cores were taken and accuracy declined, but was still improved compared to taking sextant biopsies. One possible explanation for this finding would be the change in pathologists' interpretation of the biopsy specimens. Sampling error can also be a contributing factor.
There are limitations to our study, including those inherent in a retrospective analysis. There was a general trend toward taking more core biopsies during the study period; however this was not done with a standardized protocol. The pathology review for this study was not performed by a single pathologist, and during review of prostatectomy specimens the pathologist was not blinded to the initial biopsy involvement, which could have influenced interpretation.
CONCLUSIONS
Prostate biopsy underestimated prostatectomy Gleason score in 34% of men and bilateral involvement in 80% of those with unilateral disease on biopsy. Taking at least eight cores improves the accuracy of the prostate biopsy.
